News

Published on 30 Apr 2024 on GuruFocus.com via Yahoo Finance

Exelixis Inc (EXEL) Q1 2024 Earnings: Mixed Results Amidst Restructuring Efforts


Article preview image

Total Revenue: Reported at $425.2 million for Q1 2024, showing an increase from $408.8 million in Q1 2023, but fell short of the estimated $460.62 million.Net Income: GAAP net income reached $37.3 million, or $0.12 per share, slightly below the estimated $75.48 million.Earnings Per Share (EPS): GAAP diluted EPS was $0.12, significantly below the estimated $0.24; Non-GAAP diluted EPS stood at $0.17.Research and Development Expenses: Decreased to $227.7 million in Q1 2024 from $234.2 million in the same period last year, reflecting a more focused allocation of resources.Selling, General and Administrative Expenses: Reduced to $114.0 million from $131.4 million year-over-year, indicating effective cost management.Restructuring Expenses: Incurred $32.8 million related to severance, employee-related costs, and asset impairments.Share Repurchase Program: $190.7 million worth of common stock repurchased at an average price of $22.08 per share as part of ongoing shareholder return initiatives.

Warning! GuruFocus has detected 3 Warning Signs with EXEL.

NASDAQ.EXEL price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Exelixis's SWOT analysis: cabozantinib drives growth as stock faces ip...

Exelixis, Inc. (NASDAQ:EXEL), a biotechnology company specializing in the development and...

Investing.com 15 Jan 2025

Zacks Industry Outlook Highlights Incyte, BioMarin, Exelixis, Halozyme and...

Estimates for 2024 loss per share have narrowed to 96 cents from $1.29 in the past 90 days....

Zacks · via Yahoo Finance 15 Jan 2025

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with t...

Zacks · via Yahoo Finance 13 Jan 2025

Exelixis Provides Preliminary 2024 Results and Outlook for 2025

This is the third stock repurchase program undertaken by Exelixis since March 2023. Under this...

Zacks · via Yahoo Finance 13 Jan 2025

FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib

Exelixis, Inc. EXEL announced that the FDA has notified it about an update to its supplemental ne...

Zacks · via Yahoo Finance 11 Jan 2025

Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?

EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabomety...

Zacks · via Yahoo Finance 7 Jan 2025

Is Exelixis, Inc. (EXEL) the Best Performing Biotech Stock in 2024?

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we...

Insider Monkey · via Yahoo Finance 23 Dec 2024

Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations

Quote Some better-ranked drugmakers are Novartis NVS, Gilead GILD and Exelixis EXEL, with a Zacks...

Zacks · via Yahoo Finance 18 Dec 2024

Top Research Reports for JPMorgan Chase, UnitedHealth & Verizon

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase...

Zacks · via Yahoo Finance 16 Dec 2024

Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?

Utilizing ratios like P/E, PEG, Price/Sales...Flow, the Value Style Score identifies the most...

Zacks · via Yahoo Finance 25 Nov 2024